Predict your next investment

HEALTHCARE | Drug Delivery
epitarget.com

See what CB Insights has to offer

Founded Year

2000

Stage

Series A | Alive

Total Raised

$1.62M

Last Raised

$1.23M | 15 yrs ago

About Epitarget

Developer of chemotherapeutic cancer treatment technologies. The company develops technology based on acoustic energy designed to release active substances from chemo or radiation sensitizers, which are wrapped in liposomes and directed at tumors and cancerous areas. The technology is intended to avoid causing toxicity in healthy tissue.

Epitarget Headquarter Location

GlaxoSmithKline Innovation Centre 1st Floor (2. etage), Forskningsveien 2A

Oslo, 0373,

Norway

47 23 20 12 00

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Epitarget

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Epitarget is included in 1 Expert Collection, including Nanobiotechnology.

N

Nanobiotechnology

704 items

These companies apply nanotechnology to clinical medicine. They research or develop highly specific, nanoscale interventions to aid in screening, diagnosis, and treatment of biological systems.

Epitarget Patents

Epitarget has filed 3 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/8/2010

12/9/2014

Drug delivery devices, Dosage forms, Colloidal chemistry, Biotechnology, Pharmacokinetics

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

6/8/2010

00/00/0000

00/00/0000

Grant Date

12/9/2014

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Related Topics

Drug delivery devices, Dosage forms, Colloidal chemistry, Biotechnology, Pharmacokinetics

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.